394 related articles for article (PubMed ID: 30088545)
1. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Ferreira RS; D'Ancona CAL; Oelke M; Carneiro MR
Einstein (Sao Paulo); 2018 Aug; 16(3):eAO4207. PubMed ID: 30088545
[TBL] [Abstract][Full Text] [Related]
2. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
11. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
12. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
Leitner L; Walter M; Freund P; Mehnert U; Michels L; Kollias S; Kessler TM
BMC Urol; 2014 Aug; 14():68. PubMed ID: 25132340
[TBL] [Abstract][Full Text] [Related]
13. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
Krhut J; Samal V; Nemec D; Zvara P
Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
15. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial.
Giannantoni A; Gubbiotti M; Rubilotta E; Balzarro M; Antonelli A; Bini V
Minerva Urol Nephrol; 2022 Oct; 74(5):625-635. PubMed ID: 33769020
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Honda M; Yokoyama O; Takahashi R; Matsuda T; Nakayama T; Mogi T
Int J Urol; 2021 Sep; 28(9):906-912. PubMed ID: 34075630
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.
Rovner E; Kohan A; Chartier-Kastler E; Jünemann KP; Del Popolo G; Herschorn S; Joshi M; Magyar A; Nitti V
J Urol; 2016 Sep; 196(3):801-8. PubMed ID: 27091236
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
[TBL] [Abstract][Full Text] [Related]
20. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Chen G; Liao L
Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
